Immunohematology Market Size & Share, by Product (Analyzers, Reagents, Kits); End user; Test Type; Application; Technology - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2025-2034

Immunohematology Market - Regional Analysis

North America Market Insights

North America in the immunohematology market is considered the dominant region, with the highest market share of 38.4% by the end of 2034, along with a growth rate of 6.7%. The U.S. is readily driving the market in the region, owing to Medicare’s yearly spending for blood safety evaluations, and a surge in the SCD prevalence. In addition, automated analyzers currently conduct 75% of blood typing in hospitals, thereby diminishing errors by almost 45%. Besides, Canada has positively contributed to the market’s growth in the region, with generous investments from Ontario in NAT evaluation mandates, thereby bolstering the overall market growth.

The immunohematology industryin the U.S. is significantly growing, owing to a surge in SCD, affecting more than 100,200 patients in the country, along with extension in Medicare by allocating USD 850 million as of 2024 for blood safety tests. Besides, the CDC has reported that there has been a 47.5% increase in the adoption of automated analyzers over the past five years, thereby diminishing errors in transfusion by almost 40%. Meanwhile, federal funding for blood disease research has increased to USD 290 million through the NIH as of 2024, with AI-based cross-matching achieving insurer coverage.

The immunohematology market in Canada is also growing at a 6.5% rate, which is attributed to provincial-based healthcare investments. In this regard, Ontario has generously made an allocation of USD 460 million for blood testing as of 2024, which is one of the most effective growth drivers for the overall market in the country. Besides, hemophilia and thalassemia cases have also increased by 20% over the past five years, which is also driving the market demand. Meanwhile, the 2023 Blood Safety Directives of Health Canada have mandated nucleic acid evaluation for complete donations, thus developing a USD 130 million reagent market.

North America Immunohematology Supply Chain & Trade Facilities (2022–2025)

APAC Market Insights

Asia Pacific in the immunohematology industryis expected to be the fastest-growing region, with a market share of 22.2% during the forecast timeline. The market’s growth in the region is highly fueled by modernization in healthcare and medical, government investments, and an upsurge in blood disorder occurrence. China is one of the countries that is dominating the market’s upliftment in the region based on blood safety, and this is followed by India, wherein patients demand yearly tests. Malaysia and South Korea are close behind and are integrating automated systems, thus suitable for the market’s growth.

The market in China is gaining increased traction, and is expected to achieve 20.5% of the region’s share by the end of 2034, highly attributed to the USD 3.1 billion in yearly government expenditure on blood safety facilities. Besides, the country has reported 1.7 million patients demanding blood compatibility tests annually, with almost half of tier-1 hospitals currently integrating AI-based analyzers to cater to the overall demand. Meanwhile, a national mandate as of 2024 needs nucleic acid evaluation for all donations, thereby developing a USD 525 million reagent market.

The immunohematology market in India is steadily developing with a growth rate of 9.5%, with an estimated 2.8 million patients recorded every year, along with critical barriers in facilities, wherein almost 65% of blood banks in rural areas lack automated systems. Besides, government expenditure increased to USD 2.3 billion as of 2024, with Ayushman Bharat effectively covering 520 million for basis evaluations. Domestic manufacturers, such as Transasia Bio-Medicals, are filling gaps with USD 235 moveable analyzers, which are successfully deployed in more than 10,500 clinics, thus suitable for the market growth.

Europe Market Insights

Europe in the immunohematology market is anticipated to account for a considerable share of 28.2% by the end of the projected duration, along with a 5.9% growth rate. The market’s upliftment in the region is readily fueled by government-backed automation, a rise in transfusion-based population, and the presence of strict regional blood safety administrations. Germany is leading the region’s share, attributed to yearly expenditure on blood products and the AMNOG law as of 2023. This is followed by France, with healthcare budget allocation to immunohematology, with the inclusion of AI-based analyzers, and the UK is close behind with generous investment from the NIH, all of which are responsible for boosting the market.

The market in Germany is gaining increased exposure, with a revenue share of 32.5%, highly fueled by the €4.7 billion yearly spending on blood safety. Besides, the Paul Ehrlich Institute (PEI) has successfully mandated genomic typing for complete donations by the end of 2025, thereby developing a €1.5 billion reagent market. Meanwhile, more than 67.5% of blood banks presently utilize AI-powered analyzers, such as Ortho Vision Max, diminishing cross-matching errors by at least 40.5%. The company also deliberately sources 61.5% of the region’s immunohematology-based APIs, exporting €805 million yearly to other nations.

The market in France is projected to grab approximately 22.7% of the region’s market, which is backed by 7.2% of its healthcare budget, accounting for €2.3 billion, which is readily offered to blood safety. The French Blood Establishment (EFS) has effectively installed 5,250 Galileo analyzers, eventually reducing test turnaround time to more than 1.5 hours. Besides, a €315 million collaboration with Sanofi has aimed to create 9.5 million cost-effective test kits yearly by the end of 2030 to cater to a rise in thalassemia incidences, which is almost 16.5% over the past five years, thereby suitable for bolstering the market in the country.

European Immunohematology Government Initiatives (2022-2025)

Sources: NHS England, UK Govt., AIFA, Ministry of Health Italy, AEMPS, Andalusia Health